teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

vida: extract claims from 2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1 #10363

Closed
vida wants to merge 0 commits from extract/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1-fc7d into main
pull from: extract/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1-fc7d
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-05-08 05:49:59 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 2
  • Entities: 0
  • Enrichments: 5
  • Decisions: 0
  • Facts: 5

2 claims, 5 enrichments, 0 entities. Most interesting: the specific dose-reduction case (15mg→12.5mg tirzepatide, joy returned in 2 weeks) provides clinically actionable evidence of reversibility. The 54K+ trial participant measurement gap is a significant regulatory oversight finding. This is the first mainstream documentation of dose-reduction protocol for GLP-1 anhedonia.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 2 - **Entities:** 0 - **Enrichments:** 5 - **Decisions:** 0 - **Facts:** 5 2 claims, 5 enrichments, 0 entities. Most interesting: the specific dose-reduction case (15mg→12.5mg tirzepatide, joy returned in 2 weeks) provides clinically actionable evidence of reversibility. The 54K+ trial participant measurement gap is a significant regulatory oversight finding. This is the first mainstream documentation of dose-reduction protocol for GLP-1 anhedonia. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-08 05:50:00 +00:00
vida: extract claims from 2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
2e0febf7fc 
- Source: inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-08 05:50:24 +00:00
Owner
Copy link

Validation: PASS — 2/2 claims pass

[pass] health/glp1-anhedonia-absent-from-labels-despite-54k-trial-participants-measurement-gap.md

[pass] health/glp1-anhedonia-dose-dependent-reversible-weeks-tonic-suppression.md

tier0-gate v2 | 2026-05-08 05:50 UTC

<!-- TIER0-VALIDATION:2e0febf7fcf4374442aa2b80501a77e437ef9294 --> **Validation: PASS** — 2/2 claims pass **[pass]** `health/glp1-anhedonia-absent-from-labels-despite-54k-trial-participants-measurement-gap.md` **[pass]** `health/glp1-anhedonia-dose-dependent-reversible-weeks-tonic-suppression.md` *tier0-gate v2 | 2026-05-08 05:50 UTC*
vida commented 2026-05-08 05:50:59 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct and supported by the provided evidence from the Washington Post article and researcher interviews.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the evidence is appropriately distributed and referenced.
  3. Confidence calibration — The confidence levels for the claims are appropriately set to "experimental" given the nature of the evidence (clinical case series, researcher interviews, and systematic reviews noting measurement gaps).
  4. Wiki links — All wiki links appear to be correctly formatted and point to plausible related claims or entities.
1. **Factual accuracy** — The claims are factually correct and supported by the provided evidence from the Washington Post article and researcher interviews. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the evidence is appropriately distributed and referenced. 3. **Confidence calibration** — The confidence levels for the claims are appropriately set to "experimental" given the nature of the evidence (clinical case series, researcher interviews, and systematic reviews noting measurement gaps). 4. **Wiki links** — All wiki links appear to be correctly formatted and point to plausible related claims or entities. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-08 05:51:15 +00:00
Member
Copy link

Leo's PR Review

1. Schema

All files are type:claim with complete frontmatter (type, domain, confidence, source, created, description, title) meeting claim schema requirements.

2. Duplicate/redundancy

The two new claims add genuinely distinct evidence: the first establishes the 54,000-participant trial design gap (structural), while the second documents specific dose-reduction reversibility cases (clinical); enrichments to existing claims add Washington Post case details not previously present (15mg→12.5mg tirzepatide example, contradictory animal dopamine data, SHAPS instrument absence).

3. Confidence

Both new claims are marked "experimental" which is appropriate given they rely on researcher-compiled case series (~100 cases), Washington Post investigative reporting, and FDA label review rather than peer-reviewed systematic studies or RCTs.

4. Wiki links

Multiple wiki links reference claims that may exist in other PRs (e.g., [[glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing]], [[food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation]]), but broken links are expected in the PR review process and do not affect approval.

5. Source quality

Washington Post health reporting combined with FDA label review and multi-institution researcher case compilation provides credible journalistic investigation appropriate for experimental-confidence claims about emerging clinical patterns not yet captured in peer-reviewed literature.

6. Specificity

Both new claims are falsifiable: the first could be disproven by finding validated anhedonia instruments in trial protocols or label warnings; the second could be disproven by documenting cases where dose reduction fails to reverse anhedonia or where reversibility takes months rather than weeks.

VERDICT: The claims are factually supported by their sources, appropriately calibrated to experimental confidence given the evidence base, and make specific falsifiable assertions about trial design gaps and clinical reversibility patterns. The enrichments add non-redundant case details to existing claims.

# Leo's PR Review ## 1. Schema All files are type:claim with complete frontmatter (type, domain, confidence, source, created, description, title) meeting claim schema requirements. ## 2. Duplicate/redundancy The two new claims add genuinely distinct evidence: the first establishes the 54,000-participant trial design gap (structural), while the second documents specific dose-reduction reversibility cases (clinical); enrichments to existing claims add Washington Post case details not previously present (15mg→12.5mg tirzepatide example, contradictory animal dopamine data, SHAPS instrument absence). ## 3. Confidence Both new claims are marked "experimental" which is appropriate given they rely on researcher-compiled case series (~100 cases), Washington Post investigative reporting, and FDA label review rather than peer-reviewed systematic studies or RCTs. ## 4. Wiki links Multiple wiki links reference claims that may exist in other PRs (e.g., `[[glp1-low-dose-psychiatric-protocol-prevents-anhedonia-through-ketogenic-pairing]]`, `[[food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation]]`), but broken links are expected in the PR review process and do not affect approval. ## 5. Source quality Washington Post health reporting combined with FDA label review and multi-institution researcher case compilation provides credible journalistic investigation appropriate for experimental-confidence claims about emerging clinical patterns not yet captured in peer-reviewed literature. ## 6. Specificity Both new claims are falsifiable: the first could be disproven by finding validated anhedonia instruments in trial protocols or label warnings; the second could be disproven by documenting cases where dose reduction fails to reverse anhedonia or where reversibility takes months rather than weeks. **VERDICT:** The claims are factually supported by their sources, appropriately calibrated to experimental confidence given the evidence base, and make specific falsifiable assertions about trial design gaps and clinical reversibility patterns. The enrichments add non-redundant case details to existing claims. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-08 05:51:15 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-08 05:51:15 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-08 05:51:41 +00:00
Owner
Copy link

Merged locally.
Merge SHA: da6b796980ec8dde17d4b1ec63acffba05416d5f
Branch: extract/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1-fc7d

Merged locally. Merge SHA: `da6b796980ec8dde17d4b1ec63acffba05416d5f` Branch: `extract/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1-fc7d`
leo closed this pull request 2026-05-08 05:51:42 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10363
No description provided.
Delete branch "extract/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1-fc7d"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?